Compare Edwards Lifesciences Corporation Common Stock (EW) vs i-80 Gold Corp. Common Shares (IAUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Edwards Lifesciences Corporation Common Stock vs i-80 Gold Corp. Common Shares — how do they compare? Edwards Lifesciences Corporation Common Stock trades at $87.06 (market cap $49.15B), while i-80 Gold Corp. Common Shares trades at $1.45 (market cap $1.34B). The key difference: Edwards Lifesciences Corporation Common Stock is far larger — about 36.7× i-80 Gold Corp. Common Shares's market cap, and Edwards Lifesciences Corporation Common Stock is trading nearer its 52-week high, i-80 Gold Corp. Common Shares nearer its low. Which is the better fit depends on your goals.
| EW | IAUX | |
|---|---|---|
Market Cap | $49.15B | $1.34B |
Volume | 3,642,969 | 3,239,725 |
Sector | Health | Basic Materials |
52-Week High | $95.18 | $2.08 |
52-Week Low | $72.65 | $0.89 |
Enterprise Value | $45.60B | $1.32B |
Typical Hold Time | — | 0 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Edwards Lifesciences (EW) trades at $85.27, down 1.3% with bearish technical signals. The company maintains strong fundamentals with 77.84% gross margins and recent FDA approval for the AUTUS pediatric valve. Despite a high P/E of 50.76, analysts project 20% upside to the $102.44 consensus target. Recent earnings show mixed results with Q1 and Q2 beats but a Q4 miss.
EW faces valuation concerns with declining net income margins from 17.69% to 15.43% year-over-year. Technical resistance at $86-89 and negative cash flow trends present near-term challenges. However, institutional accumulation and zero sell ratings suggest long-term confidence in structural heart growth platforms.
IAUX trades at $1.54, down 2.53% today, with a neutral technical signal. The company shows significant financial challenges with a -198.82% net income margin and negative ROE of -71.66%, though revenue grew from $95M in 2025 to $130M in 2026. Recent positive developments include CEO purchasing 1 million shares and feasibility studies showing strong potential for Nevada gold projects. Analyst consensus remains unanimously bullish with 3 buy ratings.
While facing substantial profitability challenges, IAUX's development pipeline and CEO confidence suggest long-term potential. Key risks include persistent negative cash flow from operations and high debt levels. The stock presents a high-risk, high-reward opportunity dependent on successful project execution and gold price stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Edwards Lifesciences Corporation Common Stock
Edwards Lifesciences develops medical technologies for structural heart disease. Its products include transcatheter aortic-valve replacement, mitral and tricuspid therapies, and surgical structural-heart technologies.
Read more on EW →About i-80 Gold Corp. Common Shares
i-80 Gold Corp. is a mining company focused on developing and operating gold and precious-metals projects in Nevada, using a hub-and-spoke model centered on a processing facility to support multiple mine sites in the state.
Read more on IAUX →
